HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PCPC, CHPA Ask US FDA To Defer Final Rulemaking On Sunscreen Actives In GRASE Limbo

Executive Summary

Industry continues working to support updated GRASE findings for UV filters avobenzone, homosalate, octinoxate, octisalate, octocrylene, oxybenzone, ensulizole and meradimate, which the FDA categorized more than two years ago as lacking data, a position it reprised in 2021 under its overhauled OTC monograph system.

You may also be interested in...



EWG’s 2023 Sunscreen Guide: Oxybenzone Use Down, ‘EWG Verified’ Products Up

The Environmental Working Group’s annual sunscreen report finds that one in four products evaluated meet its standards for protection and ingredient avoidance, fairly consistent with the past three years but still worse than 2019. This year, “gold standard” sunscreen products bear the nonprofit’s “Verified” mark.

US House Appropriators Seek Data On Fragrance Allergens In Cosmetics, ‘Balance’ In Sunscreen Regs

The House Appropriations Committee asks the US Food and Drug Administration to provide a report to Congress in two years on the resources it would need to develop a database for fragrance allergens used in cosmetics. The committee’s report accompanying FY2023 FDA funding legislation also touches on OTC sunscreen regulation, PFAS in cosmetics, skin-lightening ingredients, and more.

House Appropriators Hear Industry’s Self-Care Message, Ring Alarm About Menstrual Products

OTC manufacturers would add endorsements to committee’s discussion of making more consumer health products available in US. In their report, appropriators both introduced a concern and added details to an existing statement about menstrual products.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS152094

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel